• Explore /
  • Poster
  • / Encorafenib and binimetinib with or without nivolumab in treating patients with metastatic radioiodine refractory BRAF V600 mutant thyroid cancer.

Encorafenib and binimetinib with or without nivolumab in treating patients with metastatic radioiodine refractory BRAF V600 mutant thyroid cancer.

Abstract Poster

Authors

null

Matthew H. Taylor

Earle A. Chiles Research Institute, Portland, OR

Matthew H. Taylor , Rom S. Leidner , Richard Bryan Bell , Bernard Fox , Hong Xiao , Marcus Couey , Andrew Baker , George Morris , Lessli Rushforth

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04061980

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS6085)

DOI

10.1200/JCO.2021.39.15_suppl.TPS6085

Abstract #

TPS6085

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Arndt Vogel

First Author: Camila Bragança Xavier

First Author: Kangho Suh

First Author: Max Jameson-Lee